Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spago Nanomedical AB gross margin has been in long-term decline. The average rate of decline per year is -38.2%.
The historical rank and industry rank for Spago Nanomedical AB's Gross Margin % or its related term are showing as below:
OSTO:SPAGO'
s Gross Margin % Range Over the Past 10 Years
Min: -9801.65 Med: -646.68 Max: 17912.77
Current: -9801.65
During the past 13 years, the highestGross Margin % of Spago Nanomedical AB was 17912.77%. The lowest was -9801.65%. And the median was -646.68%.
OSTO:SPAGO's Gross Margin % is ranked worse than 99.59% of 732
companies
in the Biotechnology industry
Industry Median: 60.915
vs OSTO:SPAGO: -9801.65
Spago Nanomedical AB had a gross margin of -14,981.82% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Spago Nanomedical AB was -38.20% per year.
Spago Nanomedical AB (OSTO:SPAGO) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Spago Nanomedical AB had a gross margin of -14,981.82% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Spago Nanomedical AB Gross Margin % Related Terms
Spago Nanomedical AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Spago Nanomedical AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPAGO vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Spago Nanomedical AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spago Nanomedical AB Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Spago Nanomedical AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Spago Nanomedical AB (OSTO:SPAGO) has a Gross Margin % of -14,981.82% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Spago Nanomedical AB and its competitors. According to the industry distribution chart, Spago Nanomedical AB ranks #729 out of 732 companies in the Biotechnology industry, placing it in the top 99.6%.
Is Spago Nanomedical AB's Gross Margin % too high?
Spago Nanomedical AB's current Gross Margin % is -14,981.82%. Based on the distribution chart, Spago Nanomedical AB ranks #729 out of 732 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spago Nanomedical AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Spago Nanomedical AB ranks #729 out of 732 companies for Gross Margin %. This places Spago Nanomedical AB in the lower half of its industry. The industry median Gross Margin % is 60.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Spago Nanomedical AB and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spago Nanomedical AB's current Gross Margin % is -14,981.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Based on GuruFocus' analysis, Spago Nanomedical AB (OSTO:SPAGO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.03, compared to a current price of kr0.11 — trading 278.3% above its estimated fair value. The current Gross Margin % is -14,981.82%. Spago Nanomedical AB's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Spago Nanomedical AB (OSTO:SPAGO), the current Gross Margin % is -14,981.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spago Nanomedical AB (OSTO:SPAGO) Overvalued in 2026?
Based on GuruFocus' analysis, Spago Nanomedical AB stock appears to be overvalued.
The current stock price of kr0.11 is trading 278.3% above its estimated GF Value™ of kr0.03.
GuruFocus considers Spago Nanomedical AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPAGO:
Gross Margin %: -14,981.82%
GF Value™: kr0.03 vs. price of kr0.11 (278.3% above fair value)
No single metric tells the full story. See the OSTO:SPAGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
34GF Score
Get the complete analysis for OSTO:SPAGO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPAGO has been successfully added to your 
